Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib DDI Study with Itraconazole, Rifampicin, and Omeprazole
NCT04959266Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of adavosertib in solid tumor (advanced stage) (3 arms), sponsored by AstraZeneca. Primary endpoints: Ratio of geometric means of Cmax, Ratio of geometric means of AUCinf and 1 more. Started Jun 2021; status: terminated.
02
Drugs
adavosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04959266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959266.